- call +1-201-465-4211
- email sales@mrinsights.biz
Tyrosine kinase inhibitors are small molecules that bind to the receptor site of the kinase enzyme available at cell surface.
Scope of the Report:
The global tyrosine kinase inhibitors market is expanding owing to high prevalence and increase in incidence of cancer across the globe.
The worldwide market for Tyrosine Kinase Inhibitors is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
This report focuses on the Tyrosine Kinase Inhibitors in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
AstraZeneca
Pfizer
Novartis
Bristol-Myers Squibb
Bayer
Boehringer Ingelheim International
F. Hoffmann-La Roche
Johnson & Johnson
Eisai
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
BCR-ABL Tyrosine Kinase Inhibitor
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
Market Segment by Applications, can be divided into
Chronic Myeloid Leukemia (CML)
Lung Cancer
Breast Cancer
Renal Cell Cancer
Others
There are 15 Chapters to deeply display the global Tyrosine Kinase Inhibitors market.
Chapter 1, to describe Tyrosine Kinase Inhibitors Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Tyrosine Kinase Inhibitors, with sales, revenue, and price of Tyrosine Kinase Inhibitors, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Tyrosine Kinase Inhibitors, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Tyrosine Kinase Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Tyrosine Kinase Inhibitors sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Tyrosine Kinase Inhibitors Introduction
1.2 Market Analysis by Type
1.2.1 BCR-ABL Tyrosine Kinase Inhibitor
1.2.2 Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
1.2.3 Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
1.3 Market Analysis by Applications
1.3.1 Chronic Myeloid Leukemia (CML)
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Renal Cell Cancer
1.3.5 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 Business Overview
2.1.2 Tyrosine Kinase Inhibitors Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 AstraZeneca Tyrosine Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Pfizer
2.2.1 Business Overview
2.2.2 Tyrosine Kinase Inhibitors Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Pfizer Tyrosine Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis
2.3.1 Business Overview
2.3.2 Tyrosine Kinase Inhibitors Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Novartis Tyrosine Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Bristol-Myers Squibb
2.4.1 Business Overview
2.4.2 Tyrosine Kinase Inhibitors Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Bristol-Myers Squibb Tyrosine Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bayer
2.5.1 Business Overview
2.5.2 Tyrosine Kinase Inhibitors Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Bayer Tyrosine Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Boehringer Ingelheim International
2.6.1 Business Overview
2.6.2 Tyrosine Kinase Inhibitors Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Boehringer Ingelheim International Tyrosine Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 F. Hoffmann-La Roche
2.7.1 Business Overview
2.7.2 Tyrosine Kinase Inhibitors Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 F. Hoffmann-La Roche Tyrosine Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Johnson & Johnson
2.8.1 Business Overview
2.8.2 Tyrosine Kinase Inhibitors Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Johnson & Johnson Tyrosine Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Eisai
2.9.1 Business Overview
2.9.2 Tyrosine Kinase Inhibitors Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Eisai Tyrosine Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Tyrosine Kinase Inhibitors Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Tyrosine Kinase Inhibitors Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Tyrosine Kinase Inhibitors Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Tyrosine Kinase Inhibitors Manufacturer Market Share in 2017
3.3.2 Top 6 Tyrosine Kinase Inhibitors Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Tyrosine Kinase Inhibitors Market Analysis by Regions
4.1 Global Tyrosine Kinase Inhibitors Sales, Revenue and Market Share by Regions
4.1.1 Global Tyrosine Kinase Inhibitors Sales and Market Share by Regions (2013-2018)
4.1.2 Global Tyrosine Kinase Inhibitors Revenue and Market Share by Regions (2013-2018)
4.2 North America Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
4.3 Europe Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
4.5 South America Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
5 North America Tyrosine Kinase Inhibitors by Countries
5.1 North America Tyrosine Kinase Inhibitors Sales, Revenue and Market Share by Countries
5.1.1 North America Tyrosine Kinase Inhibitors Sales and Market Share by Countries (2013-2018)
5.1.2 North America Tyrosine Kinase Inhibitors Revenue and Market Share by Countries (2013-2018)
5.2 United States Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
5.3 Canada Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
5.4 Mexico Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
6 Europe Tyrosine Kinase Inhibitors by Countries
6.1 Europe Tyrosine Kinase Inhibitors Sales, Revenue and Market Share by Countries
6.1.1 Europe Tyrosine Kinase Inhibitors Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Tyrosine Kinase Inhibitors Revenue and Market Share by Countries (2013-2018)
6.2 Germany Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
6.3 UK Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
6.4 France Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
6.5 Russia Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
6.6 Italy Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
7 Asia-Pacific Tyrosine Kinase Inhibitors by Countries
7.1 Asia-Pacific Tyrosine Kinase Inhibitors Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Tyrosine Kinase Inhibitors Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Tyrosine Kinase Inhibitors Revenue and Market Share by Countries (2013-2018)
7.2 China Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
7.3 Japan Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
7.4 Korea Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
7.5 India Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
8 South America Tyrosine Kinase Inhibitors by Countries
8.1 South America Tyrosine Kinase Inhibitors Sales, Revenue and Market Share by Countries
8.1.1 South America Tyrosine Kinase Inhibitors Sales and Market Share by Countries (2013-2018)
8.1.2 South America Tyrosine Kinase Inhibitors Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
8.3 Argentina Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
8.4 Colombia Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
9 Middle East and Africa Tyrosine Kinase Inhibitors by Countries
9.1 Middle East and Africa Tyrosine Kinase Inhibitors Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Tyrosine Kinase Inhibitors Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Tyrosine Kinase Inhibitors Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
9.3 UAE Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
9.4 Egypt Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
9.5 Nigeria Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
9.6 South Africa Tyrosine Kinase Inhibitors Sales and Growth Rate (2013-2018)
10 Global Tyrosine Kinase Inhibitors Market Segment by Type
10.1 Global Tyrosine Kinase Inhibitors Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Tyrosine Kinase Inhibitors Sales and Market Share by Type (2013-2018)
10.1.2 Global Tyrosine Kinase Inhibitors Revenue and Market Share by Type (2013-2018)
10.2 BCR-ABL Tyrosine Kinase Inhibitor Sales Growth and Price
10.2.1 Global BCR-ABL Tyrosine Kinase Inhibitor Sales Growth (2013-2018)
10.2.2 Global BCR-ABL Tyrosine Kinase Inhibitor Price (2013-2018)
10.3 Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Sales Growth and Price
10.3.1 Global Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Sales Growth (2013-2018)
10.3.2 Global Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Price (2013-2018)
10.4 Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors Sales Growth and Price
10.4.1 Global Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors Sales Growth (2013-2018)
10.4.2 Global Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors Price (2013-2018)
11 Global Tyrosine Kinase Inhibitors Market Segment by Application
11.1 Global Tyrosine Kinase Inhibitors Sales Market Share by Application (2013-2018)
11.2 Chronic Myeloid Leukemia (CML) Sales Growth (2013-2018)
11.3 Lung Cancer Sales Growth (2013-2018)
11.4 Breast Cancer Sales Growth (2013-2018)
11.5 Renal Cell Cancer Sales Growth (2013-2018)
11.6 Others Sales Growth (2013-2018)
12 Tyrosine Kinase Inhibitors Market Forecast (2018-2023)
12.1 Global Tyrosine Kinase Inhibitors Sales, Revenue and Growth Rate (2018-2023)
12.2 Tyrosine Kinase Inhibitors Market Forecast by Regions (2018-2023)
12.2.1 North America Tyrosine Kinase Inhibitors Market Forecast (2018-2023)
12.2.2 Europe Tyrosine Kinase Inhibitors Market Forecast (2018-2023)
12.2.3 Asia-Pacific Tyrosine Kinase Inhibitors Market Forecast (2018-2023)
12.2.4 South America Tyrosine Kinase Inhibitors Market Forecast (2018-2023)
12.2.5 Middle East and Africa Tyrosine Kinase Inhibitors Market Forecast (2018-2023)
12.3 Tyrosine Kinase Inhibitors Market Forecast by Type (2018-2023)
12.3.1 Global Tyrosine Kinase Inhibitors Sales Forecast by Type (2018-2023)
12.3.2 Global Tyrosine Kinase Inhibitors Market Share Forecast by Type (2018-2023)
12.4 Tyrosine Kinase Inhibitors Market Forecast by Application (2018-2023)
12.4.1 Global Tyrosine Kinase Inhibitors Sales Forecast by Application (2018-2023)
12.4.2 Global Tyrosine Kinase Inhibitors Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Tyrosine Kinase Inhibitors Picture
Table Product Specifications of Tyrosine Kinase Inhibitors
Figure Global Sales Market Share of Tyrosine Kinase Inhibitors by Types
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
